Exact Mass: 688.2791960000001
Exact Mass Matches: 688.2791960000001
Found 63 metabolites which its exact mass value is equals to given mass value 688.2791960000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Halistanol sulfate
[(2S,3S,5S,6S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-2,3-disulfooxy-17-[(2R,5S)-5,6,6-trimethylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-yl] hydrogensulfate
C29H52O12S3 (688.2620751999999)
Encequidar
N-[2-(2-{4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}-2H-1,2,3,4-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide
C38H36N6O7 (688.2645345999999)
4-O-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)columbin|palmatoside C tetraacetate
4-O-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)columbin|palmatoside C tetraacetate
(7R,8S)-4,3,9-trihydroxyl-3-methoxyl-7,8-dihydrobenzofuran-1-propylneolignan-9-O-(6-O-syringoyl)-beta-D-glucopyranoside|lophantoside B
(7R,8S)-4,3,9-trihydroxyl-3-methoxyl-7,8-dihydrobenzofuran-1-propylneolignan-9-O-(6-O-syringoyl)-beta-D-glucopyranoside|lophantoside B
aeruginosin DA642B|D-o-Cl-Hpla-D-Leu-L-Choi-6-sulfate-agmatine
aeruginosin DA642B|D-o-Cl-Hpla-D-Leu-L-Choi-6-sulfate-agmatine
C29H45ClN6O9S (688.2657110000001)
rel-(4aR,6R,6aR,7S,8S,10R,11aR,12R,12aS,12bR)-5,6,6a,7,8,10,11a,12,12a-decahydro-11a-(1-hydroxy-1-methylethyl)-3,3,6a,9-tetramethyl-1H-azuleno[5,5-f][1,3]benzodioxin-6,7,8,10,12,12b(4aH)-hexol 6,7,12-triacetate 8-benzoate|sumataxin C
rel-(4aR,6R,6aR,7S,8S,10R,11aR,12R,12aS,12bR)-5,6,6a,7,8,10,11a,12,12a-decahydro-11a-(1-hydroxy-1-methylethyl)-3,3,6a,9-tetramethyl-1H-azuleno[5,5-f][1,3]benzodioxin-6,7,8,10,12,12b(4aH)-hexol 6,7,12-triacetate 8-benzoate|sumataxin C
30,30,34,34-tetrachlorocylindrocyclophane F|cylindrocyclophane F4
30,30,34,34-tetrachlorocylindrocyclophane F|cylindrocyclophane F4
2-ethylhexyl 6,6-dibutyl-14-ethyl-4,8,11-trioxo-5,7,12-trioxa-6-stannaoctadeca-2,9-dienoate
2-ethylhexyl 6,6-dibutyl-14-ethyl-4,8,11-trioxo-5,7,12-trioxa-6-stannaoctadeca-2,9-dienoate
C32H56O8Sn (688.2996966000001)
5-Hydroxy-2-(4-methoxyphenyl)-8-(2-methoxy-2-propanyl)-4-oxo-4H-furo[2,3-h]chromen-3-yl 6-deoxy-2-O-(6-deoxy-α-L-mannopyranosyl)-α-L-mannopyranoside
5-Hydroxy-2-(4-methoxyphenyl)-8-(2-methoxy-2-propanyl)-4-oxo-4H-furo[2,3-h]chromen-3-yl 6-deoxy-2-O-(6-deoxy-α-L-mannopyranosyl)-α-L-mannopyranoside
N4,N4-Di-1-naphthalenyl-N4,N4-di-2-naphthalenyl-[1,1-biphenyl]-4,4-diamine
N4,N4-Di-1-naphthalenyl-N4,N4-di-2-naphthalenyl-[1,1-biphenyl]-4,4-diamine
N,N-[2,5-O-DI-2-Fluoro-benzyl-glucaryl]-DI-[1-amino-indan-2-OL]
N,N-[2,5-O-DI-2-Fluoro-benzyl-glucaryl]-DI-[1-amino-indan-2-OL]
C38H38F2N2O8 (688.2596092000001)
4-[(10S,14S,18S)-18-(2-Amino-2-oxoethyl)-14-(1-naphthylmethyl)-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-EN-10-YL]benzylphosphonic acid
4-[(10S,14S,18S)-18-(2-Amino-2-oxoethyl)-14-(1-naphthylmethyl)-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-EN-10-YL]benzylphosphonic acid
[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA)
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA)
C28H39F3N8O9 (688.2791960000001)
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia[1].
20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15,16-tetramethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylbutanoate
20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15,16-tetramethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylbutanoate
(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r)-2-{[(2r)-3-(3-chloro-4-hydroxyphenyl)-1,2-dihydroxypropylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid
(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r)-2-{[(2r)-3-(3-chloro-4-hydroxyphenyl)-1,2-dihydroxypropylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid
C29H45ClN6O9S (688.2657110000001)
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-{4-[(2s,3r)-4-hydroxy-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-(hydroxymethyl)butyl]-2-methoxyphenoxy}oxan-2-yl]methyl 3,4-dimethoxybenzoate
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-{4-[(2s,3r)-4-hydroxy-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-(hydroxymethyl)butyl]-2-methoxyphenoxy}oxan-2-yl]methyl 3,4-dimethoxybenzoate
[9a,11a-dimethyl-7,8-bis(sulfooxy)-1-(5,6,6-trimethylheptan-2-yl)-tetradecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid
[9a,11a-dimethyl-7,8-bis(sulfooxy)-1-(5,6,6-trimethylheptan-2-yl)-tetradecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid
C29H52O12S3 (688.2620751999999)
methyl (2s)-2-(acetyloxy)-2-[(1r,2s,5r,6s,10s,11s,12r,13s,14r,15s,17r,18r)-12,14,17-tris(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,15-trimethyl-8-oxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadecan-18-yl]acetate
methyl (2s)-2-(acetyloxy)-2-[(1r,2s,5r,6s,10s,11s,12r,13s,14r,15s,17r,18r)-12,14,17-tris(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,15-trimethyl-8-oxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadecan-18-yl]acetate
methyl (2s)-2-(acetyloxy)-2-[(1s,2r,5r,6r,10r,11s,12r,13s,14r,15r,17s,18s)-12,14,17-tris(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,15-trimethyl-8-oxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadecan-18-yl]acetate
methyl (2s)-2-(acetyloxy)-2-[(1s,2r,5r,6r,10r,11s,12r,13s,14r,15r,17s,18s)-12,14,17-tris(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,15-trimethyl-8-oxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadecan-18-yl]acetate
methyl 2-[(1r,2r,5r,6r,11r,12r,13r,14s,16s)-12,14-bis(acetyloxy)-6-(furan-3-yl)-13-hydroxy-11-[(isopropoxycarbonyl)oxy]-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-9-en-16-yl]acetate
methyl 2-[(1r,2r,5r,6r,11r,12r,13r,14s,16s)-12,14-bis(acetyloxy)-6-(furan-3-yl)-13-hydroxy-11-[(isopropoxycarbonyl)oxy]-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-9-en-16-yl]acetate
(3s,6r,10r,13e,16s)-10-[(3,5-dichloro-4-methoxyphenyl)methyl]-9,12-dihydroxy-6-methyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadeca-8,11,13-triene-2,5-dione
(3s,6r,10r,13e,16s)-10-[(3,5-dichloro-4-methoxyphenyl)methyl]-9,12-dihydroxy-6-methyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadeca-8,11,13-triene-2,5-dione
C35H42Cl2N2O8 (688.2318072000002)
n-[(3r,4s,7s,10r,15as)-5,8-dihydroxy-7,10-bis(1h-indol-3-ylmethyl)-3-methyl-1,11-dioxo-3h,4h,7h,10h,13h,14h,15h,15ah-pyrrolo[2,1-c]1-oxa-4,7,10-triazacyclotridecan-4-yl]-2-phenylethanimidic acid
n-[(3r,4s,7s,10r,15as)-5,8-dihydroxy-7,10-bis(1h-indol-3-ylmethyl)-3-methyl-1,11-dioxo-3h,4h,7h,10h,13h,14h,15h,15ah-pyrrolo[2,1-c]1-oxa-4,7,10-triazacyclotridecan-4-yl]-2-phenylethanimidic acid
C39H40N6O6 (688.3009180000001)